Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook

Novartis today announced that the U.S. District Court for the District of Delaware issued a negative decision regarding the validity of a patent covering Entresto and combinations of sacubitril and valsartan, which expires in 2025 with its pediatric exclusivity. Novartis…

Read MoreNovartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook

Baxter Launches Progressa+ Next Gen ICU Bed to Help Address Complex Critical Care Needs

Baxter International Inc. (NYSE:BAX), an innovator in connected beds for med-surg and the intensive care unit (ICU), announced today the U.S. launch of its new Hillrom Progressa+ bed for the ICU. Progressa+ offers new technology and features that help make it easier for nurses…

Read MoreBaxter Launches Progressa+ Next Gen ICU Bed to Help Address Complex Critical Care Needs

CurvaFix Closes $39 Million Series C Financing Round Led by MVM Partners and Announces CEO Transition

CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the close of a $39 million equity financing led by MVM Partners with participation from Sectoral Asset Management and other existing investors. The company also announced that…

Read MoreCurvaFix Closes $39 Million Series C Financing Round Led by MVM Partners and Announces CEO Transition

DermaSensor Presents Study Results on Melanoma Detection in a Medicare Population at American Dermoscopy Meeting

DermaSensor, a health technology company equipping primary care physicians (PCPs) with a non-invasive device for use in evaluation of suspicious skin lesions, presented to the 11th Annual American Dermoscopy Meeting a sub-analysis of the DERM-ASSESS III study data focusing on…

Read MoreDermaSensor Presents Study Results on Melanoma Detection in a Medicare Population at American Dermoscopy Meeting

Big or Small, Red or Blue – States With Laws Protecting Patient Assistance Programs Have Not Seen Health Insurance Premium Hikes

The Global Healthy Living Foundation (GHLF) today refreshed a free, interactive tool showing that state laws banning accumulator and maximizer clauses in health insurance policies have not increased the cost of health insurance. In nineteen states, to date, these laws protect patient assistance programs…

Read MoreBig or Small, Red or Blue – States With Laws Protecting Patient Assistance Programs Have Not Seen Health Insurance Premium Hikes

Rising Demand for Personalized Healthcare Products Drives Global Healthcare Additive Manufacturing Market to USD 27.3 Billion by 2030 – ResearchAndMarkets.com

The global healthcare additive manufacturing market size is expected to reach USD 27.3 billion by 2030. It is expected to expand at a CAGR of 18.1% from 2023 to 2030. Healthcare additive manufacturing technology aids in making complex designs easily,…

Read MoreRising Demand for Personalized Healthcare Products Drives Global Healthcare Additive Manufacturing Market to USD 27.3 Billion by 2030 – ResearchAndMarkets.com

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2023 Financial Results

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2023. Financial Results Revenue Consolidated revenues for…

Read MoreCord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2023 Financial Results

TauRx’s Hydromethylthionine Mesylate (HMTM) Demonstrates Significant Reduction in Neurodegeneration in Alzheimer’s Disease (AD)

TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), today announced results from a prespecified analysis of the Phase 3 LUCIDITY trial that measured the impact of HMTM on neurofilament light chain (NfL), an established biomarker…

Read MoreTauRx’s Hydromethylthionine Mesylate (HMTM) Demonstrates Significant Reduction in Neurodegeneration in Alzheimer’s Disease (AD)